Globe Newswire
In-depth AutoTest provides unmatched visibility for Ethernet cable and network link validation and troubleshooting
LAS VEGAS, June 03, 2024 (GLOBE NEWSWIRE) -- Today at the Cisco Live! event, NetAlly announced the availability of its next-generation LinkRunner® AT network and cable testers, continuing a twenty-plus year legacy of innovative troubleshooting tools for network engineers and technicians.
The LinkRunner AT 3000 delivers fast and comprehensive validation... (continue reading...)
Following the IXOPAY and TokenEx merger, new leadership strengthens the company’s market position and serves the evolving needs of customers
TULSA, Okla., June 03, 2024 (GLOBE NEWSWIRE) -- Today, IXOPAY, announced the appointment of industry veteran Brady Harris as its new CEO. His appointment aligns with the recent merger of IXOPAY and TokenEx, highlighting a significant shift in the payments industry towards a multi-processor payment model, which empowers merchants... (continue reading...)
PRESS RELEASE
BIOPHTA raises 6.5 million Euros Seed Funding to transition its New Standard of Care for Eye Diseases to the Clinical stage
- The seed round was co-led by UI Investissement (via the Pertinence Invest 2 Fund, advised by Mérieux Equity Partners), Elaia and GO Capital, with participation from one major ophthalmology player, Unither Pharmaceuticals and HTL Biotechnology, the global leader in production and development of pharma grade biopolymers.
- Proceeds to... (continue reading...)
— AMD Ryzen™ AI 300 Series Processors Unlock Transformational AI Experiences for Windows Copilot+ PCs —
— AMD Ryzen™ 9000 Series Processors Set New Standards in Efficiency, Performance, and Content Creation —
TAIPEI, Taiwan, June 02, 2024 (GLOBE NEWSWIRE) -- Today, during Computex 2024, AMD (NASDAQ: AMD) announced a groundbreaking series of next-generation architecture and products aimed at ushering in a new era of AI experiences. AMD is introducing new... (continue reading...)
— Updated AMD Instinct accelerator roadmap brings annual cadence of leadership AI performance and memory capabilities —
— New AMD Instinct MI325X accelerator expected to be available in Q4 2024 with up to 288GB of HBM3E memory; new AMD Instinct MI350 series accelerators based on AMD CDNA 4 architecture expected to be available in 2025 with 35x generational increase in AI inference performance —
TAIPEI, Taiwan, June 02, 2024 (GLOBE NEWSWIRE) -- At... (continue reading...)
More Globe Newswire
View Older Stories-
AMD Extends AI and High-Performance Leadership in Data Center and PCs with New AMD Instinct, Ryzen and EPYC Processors at Computex 2024
-
Flash News: OKX Launches 100% Fee Rebate Campaign
-
Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial
-
Mesoblast Corporate Presentation at Investor Conference
-
HUTCHMED Highlights Publication of Phase III FRUTIGA Results in Nature Medicine
-
Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Telix Completes TLX250-CDx (Zircaix™) BLA Submission for Kidney Cancer Imaging
-
Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma
-
Allergic diseases directly cost between 1,800 and 6,600 euros per patient per year
-
Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting
-
KFSHRC Successfully Treats Severe Case of "Xanthoma" After 26 Years of Suffering
-
KFSHRC Successfully Treats Severe Case of "Xanthoma" After 26 Years of Suffering
-
Flash News: OKX Now Supports Wormhole Protocol's W Token on Ethereum Mainnet
-
Flash News: OKX Now Supports Wormhole Protocol's W Token on Ethereum Mainnet
-
Seer Technology Access Center Provides Unprecedented Scale and Depth of Coverage for PrognomiQ’s Early Cancer Detection Study
-
Precede Biosciences Presents New Data at ASCO 2024 Demonstrating Accurate HER2 Status Detection Across Multiple Cancers and the Ability to Quantify ER Pathway Activation in Breast Cancer from a Simple
-
ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer
-
Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 The
-
BIIB INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024
-
NVIDIA Enables Real-Time Healthcare, Industrial and Scientific AI Applications at the Edge With Enterprise Software Support for NVIDIA IGX With Holoscan
-
NVIDIA Robotics Adopted by Industry Leaders for Development of Tens of Millions of AI-Powered Autonomous Machines
-
Robotic Factories Supercharge Industrial Digitalization as Electronic Makers Adopt NVIDIA AI and Omniverse
-
NVIDIA Brings AI Assistants to Life With GeForce RTX AI PCs
-
Computer Industry Joins NVIDIA to Build AI Factories and Data Centers for the Next Industrial Revolution
-
NVIDIA Supercharges Ethernet Networking for Generative AI
-
GDRX INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that GoodRx Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Case
-
NVIDIA NIM Revolutionizes Model Deployment, Now Available to Transform World’s Millions of Developers Into Generative AI Developers
-
NVIDIA Releases Digital Human Microservices, Paving Way for Future of Generative AI Avatars
-
Intellia Therapeutics Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)
-
William Miller Spearheads Launch of Pioneering OkayCoin Staking Protocol
-
CryptoHeap Launches Comprehensive Strategy for Crypto Staking Amidst Market Fluctuations
-
BioCryst Presents New Real-world Evidence Showing Reductions in Attack Rates in HAE Patients with Normal C1-Inhibitor after Beginning ORLADEYO® (berotralstat) Treatment
-
ePac Flexible Packaging Sets Strategy for Continued Double-Digit Growth
-
BIOGEN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Biogen Inc. and Encourages Investors to Contact the Firm
-
Heineken® Celebrates Thousands of ‘Real Hardcore Fans’ by Helping Them Take Part in the UEFA Champions League Final Trophy Celebrations For The First Time Ever
-
National Skills Champions are Honoured at the Skills Canada National Competition 2024, in Québec
-
First Federal Savings Bank and ICBA Offer Tips to Help Simplify the Homebuying Process
-
Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pretreated NSCLC EGFR Wild-type Patients and Positive Initial Data from the NSCLC EGFR Mutant Cohort
-
Union members and allies mark Injured Workers’ Day in locations across Ontario
-
Prospera Energy Inc. Announces 2023 Financial Results
-
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-sma
-
Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
-
SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical
-
Flash News: OKX Announces Position Tier Adjustments for TURBO/USDT Perpetual Futures Listing
-
ClearPoint Neuro Announces Full Market Release of SmartFrame OR™ and ClearPoint PRISM® 3T Laser Therapy System
-
Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors
-
FSLY INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Fastly, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
Y-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual Meeting
-
Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting